Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07377539 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants

A Phase 1 study, sponsored by Jazz Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
86
Enrollment target

NCT07377539: Recruiting Phase 1 study, sponsored by Jazz Pharmaceuticals.

NCT07377539 is a Phase 1 study that is actively recruiting participants, run by Jazz Pharmaceuticals. The registered enrollment target is 86 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07377539, a Phase 1 study, is actively recruiting participants, sponsored by Jazz Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
86 participants
Enrollment target

Study Summary

This is a Phase 1, double-blind, sponsor-unblinded, randomized, placebo-controlled study designed to characterize the safety, tolerability, and PK of JZP047 in healthy participants following single-ascending doses of study intervention. Additionally, the effect of food on PK following a single dose of JZP047 will be assessed through comparison of PK between the fed and fasted states.

Interventions

  • OTHER Placebo
  • DRUG JZP047

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2026-02-03
Est. Completion 2026-07-05
Phase Phase 1
Jazz Pharmaceuticals

128 total trials

What NCT07377539 shows while recruiting

NCT07377539 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT07377539 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07377539 about?

NCT07377539 is a clinical study titled "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants". This is a Phase 1, double-blind, sponsor-unblinded, randomized, placebo-controlled study designed to characterize the safety, tolerability, and PK of JZP047 in healthy participants following single-ascending doses of study intervention. Additionally, the effect of food on PK following a single dose ...

What is the current status of trial NCT07377539?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2026-02-03. Estimated completion is 2026-07-05.

What interventions are being tested in trial NCT07377539?

The interventions under investigation include: Placebo (OTHER), JZP047 (DRUG).

Who is sponsoring clinical trial NCT07377539?

This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07377539's enrollment target sits among peer trials

86 652nd of 2000 higher than 1,345 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01639508 · 86 participants · Phase 2

    Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

  • NCT03519269 · 86 participants · NA

    Navio Robotic Versus Conventional Total Knee Arthroplasty

  • NCT04132999 · 86 participants · NA

    PAP for Children With DS and OSAS

  • NCT04545957 · 86 participants · NA

    Jump: MR Simulation For Radiation Therapy Master Protocol

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07377539, the US trial registry maintained by the National Library of Medicine. NCT07377539 (small enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.